Effects of i.v. and oral 1,25-dihydroxy-22-oxavitamin D3 on secondary hyperparathyroidism in dogs with chronic renal failure

Nephrology Dialysis Transplantation

Volumn 17, Issue SUPPL. 10, 2002, Pages 46-52

  Takahashi, Fumiaki ^a   Furuichi, Tatsuya ^a   Yorozu, Keigo ^a   Kawata, Setsu ^a   Kitamura, Hidetomo ^a   Kubodera, Noboru ^a   Slatopolsky, Eduardo ^b  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic renal failure; Hypercalcaemia; OCT; Parathyroid hormone; Secondary hyperparathyroidism; Uraemic dog

Indexed keywords

22 OXACALCITRIOL; CALCITRIOL; CALCITRIOL DERIVATIVE; CALCIUM ION; COLECALCIFEROL DERIVATIVE; PARATHYROID HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOG; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENCY; DRUG RESPONSE; FEMALE; HORMONE INHIBITION; HUMAN; HYPERCALCEMIA; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; STATISTICAL SIGNIFICANCE; UREMIA;

EID: 0036408919     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.suppl_10.46     Document Type: Article

References (20)

1. Silver J, Russell J, Sherwood LM. Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 1985; 82: 4270-4273
2. Berl T, Berns AS, Huffer WE et al. 1,25-Dihydroxycholecalciferol effects in chronic dialysis: a double-blind controlled study. Ann Intern Med 1978; 88: 774-780
3. Slatopolsky E, Weerts C, Thielan J et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984;74:2136-2143
4. Brown AJ, Ritter CR, Finch JL et al. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989; 84: 728-732
5. Quarles LD, Davidai AG, Schwab SJ, Bartholomay DW, Lobaugh B. Oral calcitriol and calcium: efficient therapy for uremic hyperparathyroidism. Kidney Int 1988; 34: 840-844
6. Fukagawa M, Okazaki R, Takano K et al. Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N Eng J Med 1990; 323: 421-422
7. Tsukamoto Y, Nomura M, Takahashi Y et al. The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism. Nephron 1991;57:23-28
8. Martin KJ, Ballai S, Domoto DT, Blalock S, Weindel M. Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis: preliminary observations. Am J Kidney Dis 1992; 19: 540-545
9. Slatopolsky E, Caglar S, Pennell JP et al. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest 1971; 50: 492-499
10. Torrance AG, Nachreiner R. Human-parathyroid hormone assay for use in dogs: validation, sample handling studies, and parathyroid function testing. Am J Vet Res 1989; 50: 1123-1127
11. Cantley LK, Russell J, Lettieri D, Sherwood LM. 1,25-Dihydroxyvitamin D3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture. Endocrinology 1985; 117: 2114-2119
12. Abe J, Nakano T, Nishii Y et al. A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 1991; 129: 832-837
13. Tanaka H, Hruska KA, Seino Y et al. A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. J Biol Chem 1991; 266: 10888-10892
14. Fukagawa M, Kaname S, Igarashi T, Ogata E, Kurokawa K. Regulation of parathyroid hormone synthesis in chronic renal failure in rats. Kidney Int 1991; 39: 874-881
15. Naveh-Many T, Silver J. Effects of calcitriol, 22-oxacalcitriol, and calcipotriol on serum calcium and parathyroid hormone gene expression. Endocrinology 1993; 133: 2724-2728
16. Denda M, Finch J, Brown AJ et al. 1,25 Dihydroxyvitamin D3 and 22-oxacalcitriol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats. Kidney Int 1996;50:34-39
17. Okano T, Tsugawa N, Masuda S et al. Protein-binding properties of 22-oxa-1α,25-dihydroxyvitamin D3, a synthetic analogue of 1α, 25-dihidroxyvitamin D3. J Nutr Sci Vitaminol 1989; 35: 529-533
18. Dusso AS, Negrea L, Gunawardhana S et al. On the mechanisms for the selective action of vitamin D analogs. Endocrinology 1991; 128: 1687-1692
19. Delmez JA, Slatopolsky E. Its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 1992; 19:303-317
20. Monier-Faugere MC, Geng Z, Friedler RM et al. 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney Int 1999;55:821-832